The dour biotech market sees little to be impressed about in updates from Bicycle, Rubius, C4 and Zentalis, though well-received data gives Affimed a boost.
An academic-sponsored trial gives Affimed’s NK cell engaging approach a huge endorsement.
The Astra/Daiichi antibody-drug conjugate could eat into Roche’s breast cancer dominance, courtesy of a clinical hit in Her2-low disease.
The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
Merus regains some lost pride while Bicycle rides to even greater heights.
The young biotech is well placed to deliver its first pivotal win, but investor focus might lie elsewhere.